For Dr. Keiko Tanaka, the breaking point came on a Tuesday afternoon in January. A shipment of monoclonal antibodies her team at a Honolulu research hospital had ordered six weeks earlier still had not arrived. The supplier blamed a warehouse backlog. The distributor blamed the supplier. Meanwhile, a federally funded clinical trial sat idle, burning through grant money at roughly four thousand dollars a day with nothing to show for it.

“I spent more time chasing purchase orders than analyzing data,” Tanaka said. “It felt like the entire system was designed to slow us down.”

Her frustration is not unusual. Across the life sciences industry, lab procurement remains one of the most stubbornly analog processes in an otherwise technology-driven field. Researchers, lab managers, and procurement officers routinely navigate a patchwork of vendor catalogs, paper-based approval chains, and disconnected enterprise systems just to keep shelves stocked with the reagents, consumables, and equipment that keep experiments running.

Now, a growing wave of digital procurement marketplaces is attempting to fix what many in the industry describe as a fundamentally broken system — one that wastes billions of dollars annually and, perhaps more critically, wastes the time of scientists who would rather be doing science.

The scope of the problem

The numbers paint a stark picture. According to a recent Entrepreneur UK report, 67 percent of lab professionals say they would not recommend their current procurement process. Nearly 9 in 10 researchers report that their experiments have been delayed by supplier backorders. And the administrative burden is staggering: procurement teams at mid-size biotech firms spend upward of 20 hours per week on order confirmations, invoice reconciliation, and vendor communications alone.

For an industry where time is measured in grant cycles and patent clocks, those lost hours carry real financial weight. Deloitte has estimated that the average cost of bringing a single drug to market now exceeds 2.3 billion dollars. Every week a researcher spends troubleshooting a supply chain hiccup rather than running assays is a week that compounds that cost.

The root cause is fragmentation. A typical mid-stage biotech company might work with anywhere from 50 to 200 individual suppliers. Each relationship requires its own onboarding process — which industry data suggests takes between 16 and 26 days per new vendor — its own invoicing terms, and its own communication channel. There is rarely a single dashboard where a lab manager can see what has been ordered, what has shipped, and what is stuck in limbo.

“Lab procurement has historically been treated as a back-office function,” said Marcus Chen, a supply chain analyst at a Boston-based life sciences consulting firm. “But when you look at how much money and time it actually consumes, it becomes clear that it’s a strategic bottleneck.”

The marketplace model

The concept is borrowed from consumer e-commerce: aggregate millions of products from thousands of suppliers into a single searchable interface, layer in price comparison and availability data, and let buyers make informed decisions without having to manage each vendor relationship individually.

Several companies have entered this space with varying approaches. Quartzy, based in the Bay Area, has focused on inventory management and ordering for academic labs. Labviva targets procurement compliance and catalog management for larger pharmaceutical organizations. Scientist.com operates a marketplace for outsourced research services. Each addresses a different slice of the procurement puzzle.

Among the more comprehensive platforms is ZAGENO, a Berlin-and-Boston-based company that has built what it describes as a full-stack procurement marketplace for the life sciences. The platform aggregates more than 50 million SKUs from over 6,000 suppliers, providing a single point of access for everything from pipette tips to mass spectrometers. It integrates directly with enterprise resource planning systems like SAP, Oracle, and Coupa, which means orders placed through the marketplace flow automatically into a company’s existing financial workflows.

What distinguishes the marketplace approach from traditional group purchasing organizations or distributor networks is transparency. Researchers can see real-time pricing, stock levels, and estimated delivery windows across competing suppliers — information that was previously scattered across dozens of vendor portals or locked behind sales representatives.

“The traditional model forces scientists to become part-time purchasing agents,” said Florian Wegener, ZAGENO’s chief executive. “In science, every hour counts. The next generation of procurement technology is about giving researchers more time to push discovery forward and drive product cost savings.”

A case study in consolidation

The theoretical benefits of marketplace procurement are one thing. The practical results are another. One of the more detailed public case studies comes from Apogee Therapeutics, a Massachusetts-based biotech focused on immunology and inflammation.

Before adopting a marketplace platform, Apogee’s procurement operation was spread across 98 individual vendor relationships. Each supplier had its own catalog, ordering portal, and payment terms. The company’s finance and operations teams spent a disproportionate amount of time managing the administrative overhead of that vendor sprawl.

After consolidating through a single marketplace, the results over the first year were measurable: purchase orders dropped by 40 percent, the company recovered more than 250 hours that had previously been consumed by procurement tasks and redirected that time to research activities, and total staff time savings exceeded 200,000 dollars. The finance team alone reported savings of roughly 60,000 dollars from streamlined invoicing and reduced reconciliation work.

Those figures matter most in context. For a biotech at Apogee’s stage — post-Series A, scaling toward clinical trials — every dollar and every hour that can be redirected from operations to research accelerates the timeline toward the milestones that attract the next round of funding.

Beyond ordering: data as a procurement tool

The shift to digital marketplaces is producing a secondary effect that may prove even more consequential than the immediate efficiency gains: data.

When procurement runs through a centralized platform, every transaction generates structured data — what was ordered, from which supplier, at what price, how quickly it shipped, whether it arrived on spec. Over time, that data becomes a powerful tool for optimizing procurement strategy, from identifying suppliers with chronic fulfillment problems to spotting opportunities for volume-based pricing negotiations.

PwC has projected that 70 percent of procurement functions across industries will be significantly digitalized by 2027. In the life sciences, where procurement has lagged behind sectors like manufacturing and retail, that target represents a dramatic acceleration. Companies that have already moved to marketplace platforms are building the data infrastructure that will underpin the next round of optimization.

Gartner’s research group has gone further, forecasting that artificial intelligence applied to supply chain data will soon enable predictive procurement — systems that can anticipate when a lab will run low on a given reagent based on historical consumption patterns and automatically generate replenishment orders before a stockout occurs. Some marketplace platforms are already experimenting with this capability, using machine learning models trained on aggregated purchasing data across their user base.

“Predictive procurement sounds futuristic, but the data requirements are actually quite modest,” said Dr. Lena Hoffman, a supply chain researcher at MIT’s Center for Transportation and Logistics. “If you have 12 to 18 months of clean transaction data, you can build surprisingly accurate demand forecasting models. The platforms that are capturing that data now will have a significant head start.”

Adoption barriers remain

Despite the momentum, digital procurement marketplaces face real obstacles in the life sciences. Regulatory compliance is one: labs working under Good Manufacturing Practice or Good Laboratory Practice standards need audit trails and documentation that not every platform can provide out of the box. Integration with legacy ERP systems — some of which date to the early 2000s — remains a technical challenge. And organizational inertia is powerful. Procurement managers who have spent decades building relationships with preferred vendors are not always eager to route those relationships through a third-party platform.

There are also concerns about market concentration. If a small number of marketplace platforms come to dominate lab procurement, they could accumulate significant pricing power — the same dynamic that has played out in consumer e-commerce. Suppliers, particularly smaller specialty manufacturers, worry about margin compression in a marketplace where price transparency makes it easy for buyers to switch to the lowest bidder.

“Transparency is good for buyers, but it can create a race to the bottom for sellers,” said David Park, the chief executive of a mid-size reagent manufacturer in San Diego. “We need to make sure the marketplace model doesn’t squeeze out the niche suppliers that produce the specialized products researchers actually need.”

What comes next

The trajectory is nonetheless clear. As biotech and pharmaceutical companies face mounting pressure to control R&D costs without sacrificing speed, the manual procurement processes that have persisted for decades are becoming increasingly untenable. The companies that have adopted marketplace platforms report measurable gains in efficiency, cost savings, and researcher productivity. The companies that have not are watching.

The next frontier will likely involve deeper AI integration across the procurement lifecycle — not just demand forecasting, but supplier risk assessment, contract optimization, and regulatory compliance monitoring. Several marketplace operators have begun hiring machine learning engineers and data scientists at a pace that suggests these features are not far off.

For researchers like Dr. Tanaka in Honolulu, the appeal is straightforward. “I did not go through eight years of training to become an expert in purchase order management,” she said. “If a platform can handle that so I can focus on patient outcomes, I am interested. It is as simple as that.”

The question is no longer whether digital procurement will reshape how labs buy supplies. It is how quickly the rest of the industry will catch up.